ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
qwert0
|
270 |
60K |
13 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
270
|
60K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
qwert0
|
270 |
60K |
38 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
270
|
60K
|
38
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust appoints Sergio Duchini as Non-Executive Chairman
|
|
qwert0
|
58 |
15K |
11 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
58
|
15K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
qwert0
|
86 |
20K |
11 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust receives Orphan Drug Designation for monepantel
|
|
qwert0
|
43 |
11K |
18 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
43
|
11K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust receives Orphan Drug Designation for monepantel
|
|
qwert0
|
43 |
11K |
29 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
43
|
11K
|
29
|
|
ASX - By Stock
|
EM2 |
Re:
EM2
|
|
qwert0
|
151 |
46K |
5 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
151
|
46K
|
5
|
|
ASX - By Stock
|
CYM |
Re:
Ann: Investor Presentation
|
|
qwert0
|
124 |
32K |
7 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
124
|
32K
|
7
|
|
ASX - By Stock
|
CYM |
Re:
Ann: Investor Presentation
|
|
qwert0
|
124 |
32K |
11 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
124
|
32K
|
11
|
|
ASX - By Stock
|
CYM |
Re:
Ann: Investor Presentation
|
|
qwert0
|
124 |
32K |
16 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
124
|
32K
|
16
|
|
ASX - By Stock
|
CYM |
Re:
Ann: Investor Presentation
|
|
qwert0
|
124 |
32K |
11 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
124
|
32K
|
11
|
|
ASX - By Stock
|
CYM |
Re:
Ann: Investor Presentation
|
|
qwert0
|
124 |
32K |
8 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
124
|
32K
|
8
|
|
ASX - By Stock
|
EM2 |
Re:
Ann: Mineral Resource Estimate Increased to 28Mt @ 1.35% Copper
|
|
qwert0
|
75 |
29K |
3 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
75
|
29K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
qwert0
|
1.4K |
354K |
16 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
1.4K
|
354K
|
16
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
qwert0
|
1.4K |
354K |
24 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
1.4K
|
354K
|
24
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
qwert0
|
83 |
23K |
10 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
83
|
23K
|
10
|
|
ASX - By Stock
|
EM2 |
Re:
EM2
|
|
qwert0
|
151 |
46K |
5 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
151
|
46K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
qwert0
|
250 |
61K |
29 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
250
|
61K
|
29
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
qwert0
|
250 |
61K |
19 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
250
|
61K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
qwert0
|
83 |
23K |
8 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
83
|
23K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
qwert0
|
83 |
23K |
14 |
07/05/24 |
07/05/24 |
ASX - By Stock
|
83
|
23K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
qwert0
|
261 |
70K |
17 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
261
|
70K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
qwert0
|
261 |
70K |
38 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
261
|
70K
|
38
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
qwert0
|
77 |
19K |
11 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
77
|
19K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
qwert0
|
77 |
19K |
10 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
77
|
19K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
qwert0
|
77 |
19K |
28 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
77
|
19K
|
28
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
qwert0
|
77 |
19K |
41 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
77
|
19K
|
41
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
qwert0
|
77 |
19K |
17 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
77
|
19K
|
17
|
|
ASX - By Stock
|
EM2 |
Re:
EM2
|
|
qwert0
|
151 |
46K |
3 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
151
|
46K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
NZT gone but hasn't forgotten
|
|
qwert0
|
66 |
18K |
21 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
66
|
18K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
NZT gone but hasn't forgotten
|
|
qwert0
|
66 |
18K |
21 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
66
|
18K
|
21
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
qwert0
|
1.4K |
354K |
21 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
1.4K
|
354K
|
21
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
qwert0
|
1.4K |
354K |
18 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
1.4K
|
354K
|
18
|
|
ASX - By Stock
|
EM2 |
Re:
Ann: Entitlement Offer Closes Raising $4.18 million
|
|
qwert0
|
37 |
10K |
5 |
24/03/24 |
24/03/24 |
ASX - By Stock
|
37
|
10K
|
5
|
|
ASX - By Stock
|
EM2 |
Re:
Letter to share holders
|
|
qwert0
|
20 |
9.3K |
5 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
20
|
9.3K
|
5
|
|
ASX - By Stock
|
EM2 |
Re:
Ann: Entitlement Offer Closes Raising $4.18 million
|
|
qwert0
|
37 |
10K |
7 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
37
|
10K
|
7
|
|
ASX - By Stock
|
EM2 |
Re:
EM2
|
|
qwert0
|
151 |
46K |
8 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
151
|
46K
|
8
|
|
ASX - By Stock
|
EM2 |
Re:
Ann: Renounceable Entitlement Offer - Close Date Extended
|
|
qwert0
|
27 |
7.1K |
1 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
27
|
7.1K
|
1
|
|
ASX - By Stock
|
EM2 |
Re:
Ann: Renounceable Entitlement Offer - Close Date Extended
|
|
qwert0
|
27 |
7.1K |
1 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
27
|
7.1K
|
1
|
|
ASX - By Stock
|
EM2 |
Re:
EM2
|
|
qwert0
|
151 |
46K |
2 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
151
|
46K
|
2
|
|
ASX - By Stock
|
EM2 |
Re:
EM2
|
|
qwert0
|
151 |
46K |
2 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
151
|
46K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Interim Analyses of Clinical Trials
|
|
qwert0
|
185 |
49K |
5 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
185
|
49K
|
5
|
|
ASX - By Stock
|
EM2 |
Re:
Ann: Renounceable Entitlement Offer - Close Date Extended
|
|
qwert0
|
27 |
7.1K |
15 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
27
|
7.1K
|
15
|
|
ASX - By Stock
|
EM2 |
Re:
Ann: Renounceable Entitlement Offer - Close Date Extended
|
|
qwert0
|
27 |
7.1K |
4 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
27
|
7.1K
|
4
|
|
ASX - By Stock
|
EM2 |
Re:
EM2 Chart
|
|
qwert0
|
179 |
60K |
1 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
179
|
60K
|
1
|
|
ASX - By Stock
|
EM2 |
Re:
EM2 Chart
|
|
qwert0
|
179 |
60K |
3 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
179
|
60K
|
3
|
|
ASX - By Stock
|
EM2 |
Re:
EM2 Chart
|
|
qwert0
|
179 |
60K |
0 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
179
|
60K
|
0
|
|
ASX - By Stock
|
EM2 |
Re:
EM2 Chart
|
|
qwert0
|
179 |
60K |
3 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
179
|
60K
|
3
|
|
ASX - By Stock
|
EM2 |
Re:
EM2 Chart
|
|
qwert0
|
179 |
60K |
0 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
179
|
60K
|
0
|
|
ASX - By Stock
|
EM2 |
Re:
Ann: Mid-Tier Copper Production Focus for Scoping Study
|
|
qwert0
|
25 |
10K |
0 |
01/02/24 |
01/02/24 |
ASX - By Stock
|
25
|
10K
|
0
|
|